Q1: Nosocomial (Hospital-Acquired) Infections in the ICU [10 Marks]

Definition

Predisposing Factors in ICU Patients

1. Host factors: Impaired immunity (critical illness, malnutrition, immunosuppression), extremes of age
2. Invasive devices: Endotracheal tubes, central venous catheters (CVCs), urinary catheters - each creating a direct conduit bypassing normal host barriers
3. Prolonged hospitalization: Duration of mechanical ventilation, ICU stay, and catheterization all increase risk
4. Antibiotic pressure: Prior/prolonged broad-spectrum antibiotic use promotes emergence of resistant organisms (MRSA, Pseudomonas, Acinetobacter)
5. Surgical stress: Anastomotic leaks, GI perforation, postoperative state

Types of Nosocomial Infections in ICU

1. Ventilator-Associated Pneumonia (VAP)

• Early-onset VAP (within 48-72 hours of intubation): caused by relatively antibiotic-sensitive oral flora - Haemophilus influenzae, Streptococcus pneumoniae, methicillin-sensitive S. aureus (MSSA). Associated with zero to low attributable mortality.
• Late-onset VAP (>72 hours): associated with virulent, drug-resistant organisms - MRSA, Pseudomonas aeruginosa, Acinetobacter. Associated with higher mortality.

• VAE (ventilator-associated event) surveillance requires no radiologic data to reduce subjectivity
• Invasive diagnosis: tracheal aspirate (preferred) or bronchoalveolar lavage (BAL)
• Quantitative thresholds: BAL ≥10^4 CFU/mL; protected brush specimen ≥10^3 CFU/mL

2. Catheter-Related Bloodstream Infection (CRBSI / CLABSI)

1. Clinical suspicion of catheter-related infection (low likelihood of infection elsewhere)
2. Positive blood culture drawn through the catheter or catheter segment
3. Matching positive blood culture from a peripheral site

• Strict aseptic technique with full barrier precautions during insertion
• Chlorhexidine and silver sulfadiazine-coated, or rifampin/minocycline-coated catheters (effective after day 5-6; CDC recommends if expected duration >5 days and local CRBSI rate is high)
• Daily review of the need for continued catheterization
• Routine catheter guidewire exchange is NOT recommended

3. Catheter-Associated Urinary Tract Infection (CAUTI)

• The second most common source of infection in the ICU; occurs in up to one-third of ICU patients
• Incidence increases with duration of bladder catheterization
• Bacteremia complicates ~5% of CAUTIs
• Organisms: Staphylococci, Enterococcus, enteric gram-negative bacteria, Pseudomonas
• Prevention: Careful aseptic technique during insertion, minimize catheterization duration, daily assessment of catheter necessity

4. Nosocomial Sinusitis

• Common in patients with indwelling oral and nasal tubes
• Nasotracheal intubation: ~95% radiographic sinusitis at 1 week
• Orotracheal intubation: ~25% radiographic sinusitis at 1 week
• Only ~10% of radiographic sinusitis is truly infected (by quantitative culture)
• May be responsible for 16% of fevers of unknown origin in surgical ICU
• Organisms: Same as VAP (Staphylococci, Pseudomonas, Acinetobacter)
• Prevention/Treatment: Semirecumbent positioning, avoid nasal tubes; nasal irrigation, decongestants; ENT consultation if no resolution in 2-3 days

5. Invasive Fungal Infections (Candida)

• Candida species cause the vast majority in non-neutropenic ICU patients
• Risk factors: CVCs, recent abdominal surgery/anastomotic leakage, dialysis, parenteral nutrition (PN), prolonged broad-spectrum antibiotics, corticosteroids
• Candida albicans accounts for ~50% of invasive Candida infections
• Diagnosis: Positive sterile fluid culture (gold standard; takes 72-96 hours, sensitivity ~50%); β-D-glucan assay (~80% sensitive and specific); PCR (>90% sensitivity, results in hours)
• Treatment: Echinocandins (caspofungin, micafungin, anidulafungin) are first-line in most ICU settings. Continue for at least 2 weeks after last positive blood culture. Remove intravascular catheters. Ophthalmologic exam for endophthalmitis.
• Prophylaxis: Fluconazole for high-risk patients only (not general use - promotes resistant species like C. glabrata, C. krusei)

Empiric Antibiotic Regimens (ICU)

Note: Always tailor to local antibiogram and de-escalate once culture results are available.

General Principles of Prevention

1. Hand hygiene - the single most effective measure
2. Aseptic technique for all device insertions
3. Bundle approach - bundles of care for VAP, CLABSI, CAUTI
4. Antibiotic stewardship - appropriate antibiotic use to prevent resistance
5. Minimize device duration - daily review of need for all invasive devices
6. Infection surveillance - active monitoring through NHSN (CDC)

Q2: Role of NMDA Receptor in Pain & Gate Control Theory of Pain [10 Marks]

PART A: Role of the NMDA Receptor in Pain

Structure and Basic Pharmacology

• It is a ligand-gated ion channel permeable to Ca²+, Na⁺, and K⁺
• Requires two co-agonists for activation: glutamate (binds at the glutamate site) and glycine (binds at a co-agonist site)
• Under resting conditions, the channel is voltage-dependently blocked by Mg²+ ions - the channel only opens when the cell is sufficiently depolarized AND ligand-bound (coincidence detector)
• Blocked by ketamine and other NMDA antagonists

NMDA Receptors in Primary Nociceptive Transmission

• Primary nociceptive input is transmitted via AMPA receptors, neurokinin-1 (NK1) receptors, and calcitonin gene-related peptide (CGRP) synapses
• Glutaminergic NMDA synapses do NOT participate significantly in primary nociceptive transmission
• Even after complete NMDA blockade in the spinal cord, primary afferent nociceptive information is transmitted to the thalamus
• Therefore, NMDA antagonists have an antihyperalgesic rather than analgesic effect in the spinal cord

NMDA Receptors in Central Sensitization and Wind-Up

• Repetitive C-fiber stimulation causes progressive amplification of dorsal horn neuron responses
• With each successive nociceptive input, increasing glutamate release progressively depolarizes the postsynaptic membrane
• Once the Mg²+ block is relieved by sufficient depolarization, NMDA receptors become activated
• This generates an explosive increase in intracellular Ca²+ triggering intracellular signaling cascades

1. Increased neuronal excitability (hyperalgesia - exaggerated pain response to noxious stimuli)
2. Allodynia (pain from non-noxious stimuli)
3. Expansion of receptive fields
4. Long-term potentiation (LTP) - persistent changes in synaptic efficacy
5. Facilitation of ongoing pain

Per Barash's (Chapter 55): "Preventing NMDA receptor activation in the dorsal horn... prevents wind-up, facilitation, central sensitization, expansion of receptive fields, and long-term potentiation, all of which can lead to a chronic pain state."

Clinical Implications - Preventive Analgesia

• Goal: block the development of sustained pain by preventing NMDA-driven sensitization
• Three critical principles:
  1. Depth of analgesia must be adequate to block ALL nociceptive input
  2. Analgesic technique must cover the entire surgical field
  3. Duration must cover both surgical AND postsurgical periods

• Provides analgesia at subanesthetic blood concentrations
• Works primarily by preventing central sensitization and hyperalgesia rather than blocking primary pain transmission
• Reduces postoperative opioid requirements
• Particularly useful in opioid-tolerant patients and chronic pain patients
• IV ketamine: induction dose 1-2 mg/kg; analgesic infusion 1-2 μg/kg/hr in ICU
• Also used via intraspinal/extradural routes for chronic pain

PART B: Gate Control Theory of Pain (Melzack and Wall, 1965)

Historical Background

Neuroanatomical Basis

• C fibers (unmyelinated, slow): nociceptive afferents, transmit burning/aching pain
• Aδ fibers (thinly myelinated): nociceptive, transmit sharp/fast pain
• Aβ fibers (large diameter, myelinated, fast): non-nociceptive mechanoreceptors (touch, vibration, pressure)

• Projection neurons (T cells - transmission cells): receive convergent input from both Aβ and C fibers; send signals up the anterolateral (spinothalamic) tract to the thalamus and cortex
• Inhibitory interneurons (in the substantia gelatinosa): the "gate keepers"

The Gate Mechanism

• C fiber (nociceptive) activity predominates
• C fibers inhibit the inhibitory interneuron (indirect inhibition via interneuron)
• Inhibitory interneuron becomes inactive, releasing projection neuron from inhibition
• Projection neuron fires freely → pain signals ascend to brain

• Aβ fiber (non-nociceptive) activity predominates (e.g., rubbing injured skin, TENS)
• Aβ fibers excite the inhibitory interneuron
• Active inhibitory interneuron suppresses the projection neuron
• Projection neuron fires less → reduced pain transmission

Modifications and Expanded Understanding

1. Supraspinal modulation: Gate interactions also occur at many supraspinal relay centers, not just the spinal cord
2. Descending inhibition: The periaqueductal gray (PAG) - periventricular gray matter sends inhibitory signals descending to the dorsal horn via the raphe nuclei and locus coeruleus, releasing endorphins, serotonin, and norepinephrine
3. Multiple neurotransmitters modulate the dorsal horn gate: substance P (NK1 receptors), endorphins (μ-opioid receptors), norepinephrine (α2 receptors)
4. Psychological/cognitive input: The brain itself can modulate the gate via descending pathways - explaining the analgesic effects of distraction, stress-induced analgesia in soldiers/athletes

Clinical Applications of Gate Control Theory

Summary Table

References

• Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e - Chapters 19 (Ketamine), 55 (Acute Postoperative Pain), 57 (Critical Care Medicine)
• Eric Kandel - Principles of Neural Science, 6e - Chapter 20: Pain Perception
• Neuroscience: Exploring the Brain, 5e - Chapter 12: The Somatic Sensory System (Afferent Regulation)
• Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965;150:971.